Myomo

MYO

Market cap $42.1M

Myomo (MYO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in two upcoming investor conferences. On May 20, Myomo's President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will participate virtually in a fireside chat as part of Alliance Global P.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. (“Joe”) Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors. Mr. Manko is an accomplished investor with over 25.

Myomo (MYO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Myomo, Inc. (MYO) Q1 2026 Earnings Call Transcript

Myomo, Inc. (MYO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.08 per share a year ago.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026. “Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing market access, demonstrating operating leverag.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company and manufacturer of the MyoPro® powered arm brace, announces expanded access to the MyoPro device through Ottobock Care clinics nationwide. Ottobock Care will offer the MyoPro through its clinics across the country, helping individuals with upper extremity impairment caused by stroke, brachial plexus injury, or other neurological conditions regain function and improve quality of life. “The.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answe.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo® Mobile App, a new digital tool designed to support clinicians and patients throughout the MyoPro® experience. The Myomo Mobile App is designed to make MyoPro care more intuitive, more connected, and more data-informed. For clinicians, the app provides a str.